Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether zinc supplementation changes neonatal death compared with no zinc (with or without placebo) (very low certainty).
Zinc supplementation showed no clear difference in perinatal death compared with no zinc (with or without placebo) (low certainty).
Zinc supplementation showed no clear difference in small‐for‐gestational age or IUGR compared with no zinc (with or without placebo) (moderate certainty).
Zinc supplementation showed no clear difference in low Birthweight (< 2500 g) compared with no zinc (with or without placebo) (moderate certainty).
Dornase alfa leads to higher relative mean percentage change in FVC (% predicted) at 6 months compared with placebo or no dornase alfa treatment (high certainty).
Dornase alfa showed no clear difference in change in quality of life ‐ CFQ‐R respiratory at 1 month compared with placebo or no dornase alfa treatment (low certainty).
Dornase alfa probably leads to lower number of people experiencing exacerbations at up to 2 years compared with placebo or no dornase alfa treatment (moderate certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).